We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Nanopore-Based Molecular Sensing Technology to Advance Infectious Disease Diagnostics

By LabMedica International staff writers
Posted on 18 Apr 2023
Print article
Image: The partnership will bring nanopore sequencing to the infectious disease diagnostics market (Photo courtesy of Oxford Nanopore)
Image: The partnership will bring nanopore sequencing to the infectious disease diagnostics market (Photo courtesy of Oxford Nanopore)

Nanopore-based sequencing is an innovative technology that facilitates the analysis of long DNA or RNA fragments by detecting changes in electrical current as nucleic acids pass through a protein nanopore. The signal produced is then decoded to reveal the specific DNA or RNA sequence. This technology's real-time, scalable capabilities make it perfect for quickly and cost-effectively characterizing pathogens in clinical samples. A new partnership now seeks to enhance global health outcomes by exploring opportunities to introduce nanopore sequencing to the infectious disease diagnostics market.

Oxford Nanopore Technologies (Oxford, UK) and bioMérieux SA (Marcy-L’etoile, France) have joined forces to investigate selected opportunities for advancing patient care by providing access to nanopore-based clinical research and in vitro diagnostic (IVD) solutions. Initial collaboration areas include a test for determining antibiotic resistance in tuberculosis; an assay for identifying pathogens in typically sterile clinical samples; and validating Oxford Nanopore's sequencing platform alongside BIOMÉRIEUX EPISEQ CS application for swift infection outbreak monitoring in patient-care environments.

With the ability to rapidly and accurately identify microbial pathogens and related antimicrobial resistance, Oxford Nanopore is uniquely equipped to deliver nanopore-based sequencing solutions that yield comprehensive results and expedite the process for infectious disease research and diagnostic applications. The company has devised a new generation of nanopore-based sensing technology for real-time, high-performance, accessible, and scalable analysis of DNA and RNA. This technology is employed in over 120 countries to study human biology and diseases such as cancer, as well as plants, animals, bacteria, viruses, and entire ecosystems.

“We are pleased to partner with bioMérieux’s IVD expertise to add powerful new tools for the fight against infectious disease,” said Gordon Sanghera, Oxford Nanopore Technologies Chief Executive Officer. “By offering rapid and accurate identification of pathogens and associated antimicrobial resistance, at scale, we hope to better equip the specialists for whom speed and access to comprehensive data is key.”

“We are excited to enter into a research partnership with Oxford Nanopore in the field of infectious diseases,” added Alexandre Mérieux, bioMérieux Chairman and CEO. “New technologies such as sequencing hold promise to improve diagnostics and patient care; our teams will collaborate in this direction.”

Related Links:
Oxford Nanopore Technologies
bioMérieux SA

Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Luteinizing Hormone Assay
DRG LH-Serum ELISA Kit
New
PSA Test
Humasis PSA Card

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more